Hotsia.Com : เที่ยวสะใจ

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

---

CKD and hypertension management

Chronic Kidney Disease (CKD) and hypertension are closely related, with each condition contributing to the progression of the other. Hypertension is both a cause and consequence of CKD, and it is present in about 85-90% of CKD patients, particularly in the later stages. Effective management of hypertension is critical in slowing the progression of CKD, preventing cardiovascular complications, and improving patient outcomes.

Pathophysiology of Hypertension in CKD

Hypertension in CKD is driven by a combination of factors, including volume overload, activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system overactivity, and structural changes in the kidneys. As CKD progresses, these mechanisms become more pronounced, leading to persistent and often treatment-resistant hypertension.

1. Volume Overload:

• As kidney function declines, the kidneys become less efficient at excreting sodium and water, leading to fluid retention. This volume overload increases blood pressure by raising cardiac output and peripheral vascular resistance.
• Volume overload also contributes to the development of edema (swelling, particularly in the legs) and can exacerbate heart failure in CKD patients.

2. Activation of the Renin-Angiotensin-Aldosterone System (RAAS):

• The RAAS plays a key role in regulating blood pressure by controlling sodium and water balance, as well as vascular tone. In CKD, the RAAS becomes chronically activated due to reduced perfusion to the kidneys, leading to increased production of renin, angiotensin II, and aldosterone.
• Angiotensin II is a potent vasoconstrictor that raises blood pressure by narrowing blood vessels and promoting sodium and water retention. Aldosterone further increases sodium reabsorption in the kidneys, exacerbating hypertension.

3. Sympathetic Nervous System Overactivity:

• In CKD, the sympathetic nervous system (SNS) is often overactive, contributing to increased heart rate, peripheral vasoconstriction, and sodium retention. SNS overactivity is linked to both hypertension and the progression of kidney disease.
• Chronic SNS activation also contributes to vascular damage, left ventricular hypertrophy (LVH), and cardiovascular disease in CKD patients.

4. Impaired Sodium Excretion:

• In healthy individuals, the kidneys tightly regulate sodium balance by excreting excess sodium in the urine. In CKD, however, the kidneys lose their ability to excrete sodium, leading to sodium retention and increased blood volume, which contributes to hypertension.

5. Endothelial Dysfunction:

• CKD is associated with endothelial dysfunction, which impairs the ability of blood vessels to dilate properly. This dysfunction is caused by oxidative stress, inflammation, and reduced availability of nitric oxide, a key molecule that promotes vasodilation.
• Endothelial dysfunction increases vascular resistance and contributes to the development and maintenance of hypertension.

6. Vascular Stiffness:

• In CKD, vascular calcification and arterial stiffness are common. These changes increase the rigidity of blood vessels, reducing their ability to accommodate fluctuations in blood pressure and contributing to systolic hypertension (elevated systolic blood pressure).
• Arterial stiffness also leads to increased pulse pressure (the difference between systolic and diastolic blood pressure), which is associated with an elevated risk of cardiovascular events in CKD patients.

Consequences of Uncontrolled Hypertension in CKD

Uncontrolled hypertension accelerates the progression of CKD and increases the risk of cardiovascular complications. The consequences of poorly managed hypertension in CKD include:

1. Progression of Kidney Disease:

• Hypertension damages the glomeruli (the filtering units of the kidneys) by increasing intraglomerular pressure, leading to glomerulosclerosis (scarring) and loss of kidney function. Over time, this can cause further declines in glomerular filtration rate (GFR) and progression to end-stage renal disease (ESRD).
• Hypertension also exacerbates proteinuria (the presence of excess protein in the urine), which is both a marker and a promoter of kidney damage. Proteinuria directly injures the renal tubules and interstitium, accelerating CKD progression.

2. Cardiovascular Disease:

• Hypertension is a major risk factor for cardiovascular disease (CVD) in CKD patients. It contributes to the development of left ventricular hypertrophy (LVH), a condition where the heart’s left ventricle becomes thickened and less efficient at pumping blood. LVH is strongly associated with an increased risk of heart failure, arrhythmias, and sudden cardiac death.
• CKD patients with uncontrolled hypertension are at higher risk for myocardial infarction (heart attack), stroke, and heart failure.

3. Increased Mortality:

• Studies have shown that hypertension is a significant predictor of all-cause mortality and cardiovascular mortality in CKD patients. The combination of CKD and hypertension creates a vicious cycle that accelerates both kidney and cardiovascular damage, increasing the risk of premature death.

Blood Pressure Targets in CKD

Blood pressure control is a key therapeutic goal in CKD to slow disease progression and reduce cardiovascular risk. However, optimal blood pressure targets in CKD have been the subject of debate, with guidelines recommending different targets based on individual patient factors.

• The KDIGO (Kidney Disease: Improving Global Outcomes) guidelines recommend a target blood pressure of <120/80 mmHg for CKD patients with proteinuria and <130/80 mmHg for those without proteinuria.
• The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines suggest a blood pressure target of <130/80 mmHg for most adults with CKD.
• Individualized targets may be appropriate for certain patients, particularly those with elderly age, frailty, or comorbidities such as diabetes or heart failure.

Management of Hypertension in CKD

The management of hypertension in CKD is multifaceted and includes lifestyle modifications, pharmacological therapy, and close monitoring of blood pressure and kidney function.

1. Lifestyle Modifications

Lifestyle changes are an essential component of hypertension management in CKD. These modifications can help lower blood pressure and reduce the need for medications.

• Dietary Sodium Restriction: Reducing sodium intake is critical for managing volume overload and lowering blood pressure in CKD. Sodium intake should be limited to <2,300 mg per day (approximately one teaspoon of salt). High-sodium foods, such as processed meats, canned foods, and salty snacks, should be avoided.
• Weight Loss: In overweight or obese CKD patients, weight loss can help reduce blood pressure and improve kidney function. Even modest weight loss (5-10% of body weight) can have significant benefits.
• Physical Activity: Regular physical activity, such as aerobic exercise (walking, swimming, cycling), can lower blood pressure and improve cardiovascular health. CKD patients are generally advised to engage in at least 150 minutes of moderate-intensity exercise per week, depending on their fitness level and overall health.
• Smoking Cessation: Smoking worsens kidney function, increases blood pressure, and accelerates cardiovascular disease progression. Quitting smoking is essential for CKD patients to reduce these risks.
• Moderation of Alcohol Intake: Excessive alcohol consumption can raise blood pressure. CKD patients are advised to limit alcohol intake to no more than one drink per day for women and two drinks per day for men.

2. Pharmacological Therapy

Pharmacological treatment of hypertension in CKD is typically necessary for most patients, as lifestyle changes alone are often insufficient to control blood pressure. The choice of antihypertensive medications is guided by several factors, including the presence of proteinuria, cardiovascular risk, and patient tolerance.

a. First-Line Agents

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARBs):

• ACE inhibitors (e.g., lisinopril, enalapril) and ARBs (e.g., losartan, valsartan) are the preferred first-line agents for treating hypertension in CKD patients, particularly those with proteinuria.
• These medications reduce blood pressure by blocking the RAAS, leading to vasodilation and reduced sodium retention. Additionally, ACE inhibitors and ARBs reduce intraglomerular pressure, which slows the progression of kidney disease and reduces proteinuria.
• Benefits: ACE inhibitors and ARBs have been shown to slow CKD progression, reduce proteinuria, and lower cardiovascular risk.
• Monitoring: These medications can raise serum potassium levels and worsen kidney function in some patients, so careful monitoring of serum potassium and creatinine is necessary after initiation or dose adjustments.

b. Second-Line Agents

Diuretics:

• Thiazide diuretics (e.g., hydrochlorothiazide) are effective in lowering blood pressure in patients with early-stage CKD (GFR >30 mL/min). These medications reduce blood pressure by promoting sodium and water excretion, reducing blood volume.
• In advanced CKD (GFR <30 mL/min), loop diuretics (e.g., furosemide) are preferred because they are more effective at promoting fluid and sodium excretion in patients with reduced kidney function.
• Diuretics are especially useful in managing volume overload and edema in CKD patients.

Calcium Channel Blockers (CCBs):

• Dihydropyridine CCBs (e.g., amlodipine, nifedipine) and non-dihydropyridine CCBs (e.g., diltiazem, verapamil) are often used as second-line agents in CKD patients.
• CCBs lower blood pressure by relaxing the smooth muscles in the walls of blood vessels, leading to vasodilation.
• Dihydropyridine CCBs are often combined with ACE inhibitors or ARBs when additional blood pressure control is needed.

Beta-Blockers:

• Beta-blockers (e.g., metoprolol, carvedilol) are often used in CKD patients with comorbid heart failure or coronary artery disease. They reduce blood pressure by decreasing heart rate and reducing the workload on the heart.
• Beta-blockers are typically used as adjunct therapy when blood pressure is not adequately controlled with RAAS inhibitors and diuretics.

c. Third-Line Agents

Aldosterone Antagonists:

• Aldosterone antagonists (e.g., spironolactone, eplerenone) block the effects of aldosterone, promoting sodium excretion and lowering blood pressure.
• These medications are effective in resistant hypertension, but they can increase the risk of hyperkalemia, particularly in CKD patients, so potassium levels must be carefully monitored.

Alpha-Blockers:

• Alpha-blockers (e.g., doxazosin) are sometimes used as third-line agents for treating hypertension in CKD, especially in patients with benign prostatic hyperplasia (BPH). They reduce blood pressure by relaxing blood vessels.

3. Resistant Hypertension

Resistant hypertension is defined as blood pressure that remains above target despite the use of three or more antihypertensive agents, including a diuretic. It is common in CKD due to volume overload, RAAS activation, and other factors.

• For patients with resistant hypertension, intensifying diuretic therapy, adjusting doses of RAAS inhibitors, or adding additional agents such as aldosterone antagonists may be necessary.
• Spironolactone or eplerenone can be effective in controlling resistant hypertension but should be used with caution due to the risk of hyperkalemia.
• In patients with advanced CKD or ESRD, volume overload may require more aggressive diuretic therapy or ultrafiltration during dialysis.

4. Monitoring and Follow-Up

Regular monitoring of blood pressure, kidney function, and electrolyte levels is critical in CKD patients receiving antihypertensive therapy. Patients should have their blood pressure measured at each clinic visit, and home blood pressure monitoring is encouraged for more accurate assessment of control.

• Serum creatinine and GFR should be checked regularly to assess kidney function and adjust medication doses accordingly.
• Serum potassium levels should be monitored closely, especially in patients on RAAS inhibitors, diuretics, or aldosterone antagonists, as these medications can cause hyperkalemia.

Conclusion

Hypertension is a key contributor to the progression of CKD and a major risk factor for cardiovascular disease in CKD patients. Effective management of hypertension is essential to slow the decline in kidney function, reduce proteinuria, and minimize cardiovascular risk. The management of hypertension in CKD requires a combination of lifestyle modifications, pharmacological therapy, and careful monitoring. RAAS inhibitors (ACE inhibitors and ARBs) are the first-line treatment, especially in patients with proteinuria, but diuretics, calcium channel blockers, and beta-blockers are often needed to achieve optimal blood pressure control. Regular monitoring and individualized treatment plans are crucial to ensure that CKD patients receive appropriate care and achieve the best possible outcomes.

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com